Clinical trial
An Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent Radiotherapy and Chemotherapy Following Induction Therapy With Enlonstobart Plus Chemotherapy in Patients With Locally Advanced Cervical Cancer.
NCT07776821 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent Radiotherapy and Chemotherapy Following Induction Therapy With Enlonstobart Plus Chemotherapy in Patients With Locally Advanced Cervical Cancer.
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- September 1, 2025
- Completion date
- November 1, 2026
- Enrollment
- 31 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.